Yasir Mehmood

Dr. Yasir Mehmood

Riphah International University, Faisalabad, Faisalabad, Punjab, Pakistan
orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2020 in Saudi Pharmaceutical Journal
Verified
Journal Article
Open access
YHYeteng He
Yeteng He
KMKhadija Majid
Khadija Majid
MMMaimoona Maqbool
Maimoona Maqbool
THTalib Hussain
Talib Hussain
AYAbid Mehmood Yousaf
Abid Mehmood Yousaf
YSYasser Shahzad
Yasser Shahzad
Rheumatoid arthritis (RA) is an autoimmune disease associated with severe joint pain. Herein, we report lornoxicam loaded cellulosic microsponge gel formulation with sustained anti-inflammatory effects that are required to manage arthritic pain. The microsponges were formulated using quasi emulsion-solvent diffusion method employing four different surfactant systems, namely polyvinyl alcohol (PVA), Tween80, Gelucire 48/16 and Gelucire 50/13. All the lornoxicam loaded microsponge formulations were extensively characterized with a variety of analytical tools. The optimized microsponge formulation was then converted into gel formulation. The lornoxicam loaded microsponge gel formulation had adequate viscosity and sufficient pharmaceutical properties as confirmed by the texture analysis and the drug release followed Super case II transport. It is noteworthy that we described the preparation of a new cellulosic polymers based microsponge system for delivery of lornoxicam to provide quick as well as lasting (sustained) anti-inflammatory effects in rats using carrageenan induced rat paw edema model. We were able to demonstrate a 72% reduction in inflammation within 4 h using the optimize transdermal gel formulation utilizing Transcutol P as permeation enhancer and with the aid of skin micro-piercing by microneedles, hence, demonstrating the potential of this microsponge gel formulation in arthritis management.

1 February 2020 in European Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
YMYasir Mehmood
Yasir Mehmood
IKIkram Ullah Khan
Ikram Ullah Khan
YSYasser Shahzad
Yasser Shahzad
RKRizwan Ullah Khan
Rizwan Ullah Khan
SKSyed Haroon Khalid
Syed Haroon Khalid
SSShefaat Ullah Shah
Shefaat Ullah Shah

28 March 2020 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
YMYasir Mehmood
Yasir Mehmood
IKIkram Ullah Khan
Ikram Ullah Khan
YSYasser Shahzad
Yasser Shahzad
RKRizwan Ullah Khan
Rizwan Ullah Khan
MIMuhammad Shahid Iqbal
Muhammad Shahid Iqbal
SSShefaat Ullah Shah
Shefaat Ullah Shah
The limited aqueous solubility of many active pharmaceutical ingredients (APIs) is responsible for their poor performance and low drug levels in blood and at target sites. Various approaches have been adopted to tackle this issue. Most recently, mesoporous silica nanoparticles (MSN) have gained attention of pharmaceutical scientists for bio-imaging, bio-sensing, gene delivery, drug solubility enhancement, and controlled and targeted drug release. Here, we have successfully incorporated the poorly water soluble antiviral drug velpatasvir (VLP) in MSN. These spherical particles were 186 nm in diameter with polydispersity index of 0.244. Blank MSN have specific surface area and pore diameter of 602.5 ± 0.7 m2/g and 5.9 nm, respectively, which reduced after successful incorporation of drug. Drug was in amorphous form in synthesized VLP-loaded silica particles (VLP-MSN) with no significant interaction with carrier. Pure VLP showed poor dissolution with progressive increment in pH of dissolution media which could limit its availability in systemic circulation after oral administration. After VLP loading in silica carriers, drug released rapidly over a wide range of pH values, i.e., 1.2 to 6.8, thus indicating an improvement in the solubility profile of VLP. These particles were biocompatible, with an LD50 of 448 µg/mL, and in-vivo pharmacokinetic results demonstrated that VLP-MSN significantly enhanced the bioavailability as compared to pure drug. The above results clearly demonstrate satisfactory in-vitro performance, biocompatibility, non-toxicity and in-vivo bioavailability enhancement with VLP-MSN.

1 January 2020 in International Journal of Nanomedicine
Verified
Journal Article
Open access
PDF file
RSRu Sun
Ru Sun
CSChengwu Shen
Chengwu Shen
SSShumaila Shafique
Shumaila Shafique
OMOmer Mustapha
Omer Mustapha
THTalib Hussain
Talib Hussain
AYAbid Yousaf
Abid Yousaf
Background: Bezafibrate is a BCS class II drug as it presents very low solubility in water; therefore, its bioavailability after oral administration is very poor. The aim of this work was to enhance solubility and dissolution rate of bezafibrate in water in order to enhance its oral bioavailability. Methods: Several formulations were prepared using PVP K30 and Cremophor ELP employing the solvent-evaporation method and the electrospraying technique. Solubility, release rate, bioavailability in male Sprague Dawley rats, and lipid profile attributes in Wistar rats were assessed in comparison with bezafibrate plain powder. Solid-state characterization was carried out using X-ray diffraction (XRD) analysis, differential scanning calorimetry (DSC), Fourier transform infrared (FTIR) spectroscopy and scanning electron microscopy (SEM). Results: All the formulations exerted positive effect towards the desired goal. In particular, the optimized formulation furnished about 14-fold enhanced solubility and 85.48 ± 10.16% drug was released in 10 min as compared with bezafibrate alone (4.06 ± 2.59%). The drug existed in the amorphous state in the prepared sample as confirmed by XRD and DSC, whilst no drug-excipient interactions were observed through FTIR analysis. Moreover, SEM revealed smooth-surfaced spherical particles of the optimized formulation. A 5.5-fold higher oral bioavailability was achieved with the optimized formulation in comparison with bezafibrate plain powder. Also, TG, LDL and TC were decreased, and HDL was increased considerably in HFD-treated rats. Conclusion: The optimized formulation consisting of bezafibrate, PVP K30 and cremophor ELP (1/12/1.5, w/w/w) might be a capable drug delivery system for orally administering poorly water-soluble bezafibrate with improved bioavailability and antihyperlipidemic effects.

1 July 2019
Verified
Journal Article
Closed access
YMYasir Mehmood
Yasir Mehmood
IKIkram Ullah Khan
Ikram Ullah Khan
YSYasser Shahzad
Yasser Shahzad
SKSyed Haroon Khalid
Syed Haroon Khalid
SASajid Asghar
Sajid Asghar
THTalib Hussain
Talib Hussain

12 October 2024 in Scientific Reports
Verified
Journal Article
Open access
PDF file
YMYasir Mehmood
Yasir Mehmood
HSHira Shahid
Hira Shahid
SAShabbir Ahmed
Shabbir Ahmed
AKAnjum Khursheed
Anjum Khursheed
TJTalha Jamshaid
Talha Jamshaid
FSFarhan Siddique
Farhan Siddique
The purpose of the current work was to develop and characterize ethosomes of vitamin D3 gel that could more effectively work against psoriasis. Psoriasis is a chronic immune-mediated inflammatory skin disease. Due to vitamin D3 role in proliferation and maturation of keratinocytes, it has become an important local therapeutic option in the treatment of psoriasis. In this research we have initiated worked on ethosomes gels containing vitamin D3 to treat psoriasis. Soya lecithin 1–8% (w/v), propylene glycol and ethanol were used to create the formulations, which were then tested for vesicle size, shape, surface morphology, entrapment effectiveness, and in vitro drug permeation. The drug encapsulation efficiency of ethosomes was 96.25% ± 0.3. The particle sizes of the optimized ethosomes was 148 and 657 nm, and the PDI value was 0.770 ± 0.12 along with negative charge − 14 ± 3. Fourier transform infrared (FT-IR) spectroscopy and differential scanning calorimetry (DSC) along with thermogravimetric analysis (TGA) studies confirmed the absence of interactions between vitamin D3 and other ingredients. It was determined that the total amount of medication that penetrated the membrane was 95.34% ± 3. Percentage lysis was very negligible for all strengths which were found less than 15%. Based on our research, ethosomes appear to be safe for use. The vitamin D3 ethosomal gel order, description, pH, and viscosity were all within the specified ranges, according to the findings of a 6-month investigation into the stability profile of the completed system. In this research, we successfully prepared ethosomes loaded with vitamin D3 and then converted it into gel for patients’ easy applications.